335 related articles for article (PubMed ID: 27549920)
1. Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database.
Tanabe M; Motonaga R; Terawaki Y; Nomiyama T; Yanase T
J Diabetes Investig; 2017 Mar; 8(2):227-234. PubMed ID: 27549920
[TBL] [Abstract][Full Text] [Related]
2. Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database.
Tanabe M; Nomiyama T; Motonaga R; Murase K; Yanase T
BMC Endocr Disord; 2015 Sep; 15():49. PubMed ID: 26382923
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study).
Ishii H; Hayashino Y; Akai Y; Yabuta M; Tsujii S
J Diabetes Investig; 2018 Jan; 9(1):137-145. PubMed ID: 28296349
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].
Umetsu R; Nishibata Y; Abe J; Suzuki Y; Hara H; Nagasawa H; Kinosada Y; Nakamura M
Yakugaku Zasshi; 2014; 134(2):299-304. PubMed ID: 24492232
[TBL] [Abstract][Full Text] [Related]
5. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.
Kadowaki T; Sarai N; Hirakawa T; Taki K; Iwasaki K; Urushihara H
Diabetes Obes Metab; 2018 Dec; 20(12):2830-2839. PubMed ID: 29974673
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
Araki E; Tanizawa Y; Tanaka Y; Taniguchi A; Koiwai K; Kim G; Salsali A; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2015 Jul; 17(7):665-74. PubMed ID: 25772548
[TBL] [Abstract][Full Text] [Related]
7. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study.
Inagaki N; Sano H; Seki Y; Kuroda S; Kaku K
J Diabetes Investig; 2016 Sep; 7(5):718-26. PubMed ID: 27181699
[TBL] [Abstract][Full Text] [Related]
9. [Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents].
Mori Y
Nihon Rinsho; 2011 Aug; 69(8):1505-14. PubMed ID: 21838054
[TBL] [Abstract][Full Text] [Related]
10. Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis.
Kalsekar ID; Madhavan SS; Amonkar MM; Douglas SM; Makela E; Elswick BL; Scott V
Clin Ther; 2006 Feb; 28(2):306-18. PubMed ID: 16678652
[TBL] [Abstract][Full Text] [Related]
11. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial.
Weiss SR; Cheng SL; Kourides IA; Gelfand RA; Landschulz WH;
Arch Intern Med; 2003 Oct; 163(19):2277-82. PubMed ID: 14581245
[TBL] [Abstract][Full Text] [Related]
12. Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42).
Fujihara K; Igarashi R; Matsunaga S; Matsubayashi Y; Yamada T; Yokoyama H; Tanaka S; Shimano H; Maegawa H; Yamazaki K; Kawai K; Sone H
Medicine (Baltimore); 2017 Feb; 96(7):e6122. PubMed ID: 28207538
[TBL] [Abstract][Full Text] [Related]
13. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.
Munir KM; Davis SN
Expert Opin Pharmacother; 2015; 16(15):2331-41. PubMed ID: 26340427
[TBL] [Abstract][Full Text] [Related]
14. Glycemic Control and Pregnancy Outcomes in Women with Type 2 Diabetes Treated with Oral Hypoglycemic Agents.
Feghali MN; Caritis SN; Catov JM; Scifres CM
Am J Perinatol; 2017 Jun; 34(7):697-704. PubMed ID: 27984840
[No Abstract] [Full Text] [Related]
15. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
[TBL] [Abstract][Full Text] [Related]
16. The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: An 8-year population-based study.
Chu WM; Ho HE; Huang KH; Tsan YT; Liou YS; Wang YH; Lee MC; Li YC
Medicine (Baltimore); 2017 Oct; 96(43):e8257. PubMed ID: 29068991
[TBL] [Abstract][Full Text] [Related]
17. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.
Emoto M; Terauchi Y; Ozeki A; Oura T; Takeuchi M; Imaoka T
Endocr J; 2015; 62(12):1101-14. PubMed ID: 26477324
[TBL] [Abstract][Full Text] [Related]
18. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
[TBL] [Abstract][Full Text] [Related]
19. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
[No Abstract] [Full Text] [Related]
[Next] [New Search]
